logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

ZHIHU-W (02390) spent $394,300 to buy back 347,100 shares on April 14th.

date
18:46 15/04/2026
avatar
GMT Eight
Zhihu-W (02390) announced that the company repurchased 347,100 shares on April 14, 2026, at a total cost of $394,300, with a repurchase price per share of $1.1167-1.1567.
ZHIHU-W (02390) announced that the company repurchased 347,100 shares for $394,300 on April 14, 2026, at a repurchase price of $1.1167-1.1567 per share.
Related Articles
New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.
New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.
China Stock
Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.
New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.
Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
China Stock
RECOMMEND
Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
icon
17/04/2026
Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
icon
17/04/2026
Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
icon
17/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.